RFXANK Antibody [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NB600-205IR
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Primate
Applications
Western Blot
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Peptide made to a portion of the RFX-B protein.
Reactivity Notes
Human and Primates RFX-B.
Specificity
Reacts with residues 18-31 [ASELGDPEDPGEEAC] of the RFX-B protein.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for RFXANK Antibody [DyLight 755]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: RFXANK
Alternate Names
ANKRA1Regulatory factor X subunit B, ankyrin repeat-containing regulatory factor X-associated protein, BLS, DNA-binding protein RFXANK, F14150_1, MGC138628, regulatory factor X-associated ankyrin-containing proteinAnkyrin repeat family A protein 1, RFXB, RFX-BRFX-Bdelta4
Gene Symbol
RFXANK
Additional RFXANK Products
Product Documents for RFXANK Antibody [DyLight 755]
Product Specific Notices for RFXANK Antibody [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...